Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Bariatric Surgery, Medical Weight Management.
- Кому может быть актуально
- Состояния в реестре: Cardiovascular Complication, Bariatric Surgery Candidate. Базовые параметры: от 18 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Канада
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Обзор
The primary objective of this study is to evaluate if, in patients with severe obesity (body mass index (BMI) ≥30 kg/m2) and high-risk cardiovascular disease (CVD), bariatric surgery compared to medical weight management (MWM) safely reduces the risk of major cardiovascular events. The cost-effectiveness of bariatric surgery will also be examined. Separate sub-studies will be performed to examine the relationship between bariatric surgery and mental health and cognition (BRAVE-Mind), cardiac structure and function, genomics, proteomics and metabolomics.
Вмешательства
- Процедура Bariatric Surgery
Bariatric surgery involves either gastric bypass, sleeve gastrectomy, or duodenal switch, performed at the discretion of the surgeon and according to local practice standards. - Поведенческое Medical Weight Management
The current standard medical practice for weight loss that is available at the local participating centre, reflecting the local standard of care
Первичные конечные точки
- Cardiovascular Outcomes [Срок оценки: Through study completion, expected average of 6 years]
- BRAVE-Mind Sub-study Measures [Срок оценки: 3 years]
Вторичные конечные точки (8)
- All-cause mortality [Срок оценки: Through study completion, expected average of 6 years]
- Cardiovascular mortality [Срок оценки: Through study completion, expected average of 6 years]
- Myocardial infarction [Срок оценки: Through study completion, expected average of 6 years]
- Stroke [Срок оценки: Through study completion, expected average of 6 years]
- Hospitalization for heart failure [Срок оценки: Through study completion, expected average of 6 years]
- New onset or remission of type 2 diabetes as per Diabetes Canada / American Diabetes Association Guidelines [Срок оценки: Through study completion, expected average of 6 years]
- New onset atrial fibrillation as assessed by ECG or heart rhythm monitoring [Срок оценки: Through study completion, expected average of 6 years]
- Cost effectiveness analysis, measured in quality adjusted life years [Срок оценки: Through study completion, expected average of 6 years]
Критерии участия
Критерии включения
- Body mass index ≥30 kg/m2; OR BMI ≥30 kg/m2 to 34.9 kg/m2 and have type 2 diabetes or are \>55 years of age
- Age ≥18 years
- High-risk CVD, defined as the presence of any one of the following:
- High-risk coronary artery disease (CAD) (i.e., history of MI, percutaneous coronary intervention, coronary artery bypass grafting, or stenoses ≥ 50% in 2 or more major coronary arteries)
- Left ventricular ejection fraction (LVEF) \< 40%
- Heart failure with preserved ejection fraction (LVEF \> 40%) and either HF hospitalization in the last 2-years or N-terminal pro b-type natriuretic peptide (NT-proBNP) \> 300 pg/ml or BNP \> 100 pg/ml in the past 12 months
- Documented atrial fibrillation (AF) with CHA2DS2-VASc ≥2 stroke risk score
- History of any stroke
- Documented peripheral arterial disease (PAD) (i.e., peripheral revascularization of the iliac, infra-inguinal or carotid arteries; limb or foot amputation for arterial vascular disease; or ≥50% carotid or peripheral artery stenosis)
Критерии исключения
- Hospital admission for HF, myocardial infarction, stroke or coronary revascularization within 30 days of randomization
- Percutaneous coronary intervention with a drug eluting stent within 90 days of randomization.
- Pregnancy
- Contraindication to bariatric surgery
- Prior bariatric surgery, other than gastric banding
- Life expectancy \<2 years from non-cardiovascular causes
- Inability to provide informed consent
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Распределение
- Рандомизированное
- Модель
- Параллельные группы
- Маскирование
- Открытое
- Основная цель
- Лечение
Центры проведения
Канада · 1 центр
- Hamilton Health Sciences — Hamilton
Идентификаторы
NCT: NCT05531474 · BRAVE-Full Trial